Note: This is sponsored content. The views expressed here are solely those of the author. Top News of the Day ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

A good sum of two good parts. Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most peers, over a market cycle on a ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

On July 22, 2025, Replimune revealed that the FDA had issued a Complete Response Letter (CRL) for its Biologics License Application for RP1, a novel immunotherapy aimed at treating advanced melanoma.

In Microsoft Office, a SmartArt graphic ranges from the graphical list and process diagrams to more complex graphics such as Venn diagrams and Organization charts. SmartArt is visually used to ...

Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...

Recent discussions on X about Replimune Group Inc. (REPL) have been ignited by the U.S. FDA's rejection of the company's lead drug, RP1, for melanoma treatment in combination therapy. Many users are ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...

Have you ever found yourself staring at a jumble of numbers, wishing they could magically transform into a clean, professional-looking chart? Whether you’re preparing for a big presentation, ...

Visio in Microsoft 365 is a superb tool for creating custom diagrams to illustrate concepts that are difficult to explain through text. Here’s how to use it. It’s often much easier to convey ...